An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) Abstract #1697

Introduction: Patients (pts) with advanced neuroendocrine tumors (NETs) who have failed sunitinib or everolimus have limited treatment options. Sulfatinib, a novel kinase inhibitor targeting tumor angiogenesis and immune evasion, has shown encouraging anti-tumor activity in patients with advanced NETs in a phase I study.
Aim(s): This is an open-label, single-arm study to further assess the efficacy and safety of sulfatinib in pts with advanced grade 1 or 2 NETs.
Materials and methods: Sulfatinib was orally given 300 mg, qd, until disease progression or unacceptable toxicity. Tumor responses were assessed using RECIST v 1.1.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Jian Ming Xu
Keywords: sulfatinib, net, orr, pfs

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1444 Clinical Characteristic and Treatment Options of Patients with G3 Gastroenteropancreatic Neuroendocrine Neoplasms in China
Introduction: Well differentiated neuroendocrine tumor G3 (NET G3) patients are a special part of neuroendocrine neoplasms with a different biological behavior comparing with other G3 patients.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Ru Jia
Authors: Jia R, Tan H, Bai C M, Zhang P, ...
Keywords: NET G3, NEC, TEMCAP
#2143 Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplams
Introduction: Neuroendocrine neoplasms (NENs) are a series of disease which show highly heterogeneity but have limited treatment options. Previous studies showed that tumor mutation burden (TMB) in NEC was relatively high which is considered as a predictive marker of anti-PD-1 antibody.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Ru Jia
Authors: Jia R, Li Y L, Jin Y S, Chen Y, ...
#993 Analysis of Somatostatin Receptors Expression in Neuroendocrine Tumors
Introduction: Clinical studies have suggested anti-tumor efficacy of somatostatin analog (SSA) in the treatment of neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr Tingting Li
Authors: Li T, Qian Z, Ter-Minassian M, Chan J A, ...
Keywords: SSTR2, SSA, NET, OS, PFS
#1508 NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results
Introduction: There are limited therapeutic options for patients with advanced midgut NETs progressing on first-line somatostatin analog therapy.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Jonathan Strosberg
Authors: Strosberg J, Wolin E, Chasen B, Kulke M, ...
Keywords: Lutathera, PRRT, NET
#1881 A Gene Expression-Based Nomogram Predicts Progression Free Survival in Small Bowel NETs
Introduction: Nomograms are predictive tools that help prognosticate. A survival nomogram has been validated for small bowel NETs. A circulating NET specific 51gene signature – the NETest – has efficacy (~95%) as a predictor of progression free survival (PFS).
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Professor Mark Kidd
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.